Subcutaneous administration of Inclisiran, a small-interfering RNA ( siRNA ) directed against proprotein convertase subtilisin/kexin type 9 ( PCSK9 ),...
Anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia: systematic review of published phase 3 data
Two anti-proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies, Alirocumab and Evolocumab, have been approved for the treatment...
Familial hypercholesterolaemia - Long-term efficacy and safety of Mipomersen: 2-year interim results
The objective of a study was to evaluate the efficacy and safety of extended dosing with Mipomersen ( Kynamro )...
High cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: efficacy and safety of Alirocumab versus Ezetimibe
A study has compared the efficacy [ low-density lipoprotein cholesterol ( LDL-C ) lowering ] and safety of Alirocumab (...
RNA interference drug on the synthesis of PCSK9 and the concentration of serum LDL cholesterol in healthy volunteers
Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) binds to LDL receptors, leading to their degradation. Genetics studies have shown...
Consensus Panel of ESA - Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management
Homozygous familial hypercholesterolaemia ( HoFH ) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein...
Acute coronary syndromes: reaching lower cholesterol levels with the cholesterol inhibitor Ezetimibe, in combination with a statin, reduces cardiovascular events in high-risk patients
IMPROVE-IT ( IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial ), was an international, multi-center, randomised, double-blind active comparator trial...
Statins ( HMG-CoA reductase inhibitors ) are widely used medicines for patients with lipid disorders and in the primary and...
Microsomal triglyceride transfer protein inhibitors: efficacy and safety of Lomitapide in patients with homozygous familial hypercholesterolaemia
Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. A study has assessed the efficacy and safety of the...
EMA refused the marketing authorisation for Kynamro, a drug for treatment of patients with certain forms of familial hypercholesterolaemia
On 13 December 2012, the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a negative opinion,...
Consensus Statement of the European Atherosclerosis Society on familial hypercholesterolaemia in order to prevent coronary heart disease
Of the theoretical estimated prevalence of 1/500 for heterozygous familial hypercholesterolaemia, less than 1% are diagnosed in most countries. Direct...
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease / Consensus Statement of the European Atherosclerosis Society
The first aim was to critically evaluate the extent to which familial hypercholesterolaemia ( FH ) is underdiagnosed and undertreated....
The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of...
- H1-Antihistamine Therapy
- H7N9 Virus
- Haematological Malignant Diseases
- Haemophilia A
- Hand-Foot Syndrome
- Hantavirus Infection
- Hbv Virus
- Hcv Genotype 1 Infection
- Hcv Genotype 1 Infection
- Hcv Genotype 2 Infection
- Hcv Genotype 3 Infection
- Hcv Virus